Brief: Asit Biotech announces that it has achieved primary endpoint of phase I/IIa clinical trial with its hdm-ASIT+ product candidate for house dust mite rhinitis

European Medical Solutions SA

04/04/2017 17:02

April 4 (Reuters) - Asit Biotech SA  ASIT.BR : 
    * Announces that it has achieved the primary endpoint of the phase I/IIa clinical trial with 
its hdm-ASIT+ product candidate for house dust mite rhinitis 
    * Confirmation of hdm-ASIT+'s safety and tolerability profile 
    * Conjunctival provocation test showed a slight numerical difference in favour of treated 
group compared to placebo group (not statistically significant) 
 
Source text for Eikon:  ID:nBw4GWsfha  
Further company coverage:  ASIT.BR  
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))